Longer-term studies will be necessary to confirm whether the phenotypic changes reported herein are sustained over time, but our data provide in vivo evidence that supports the therapeutic potential of reducing Fsp27 expression/activity in obese patients to reduce visceral adiposity and multiorgan insulin resistance. This evidence concerns the gene CIDEC and Insulin resistance.